Deplin® P.L.U.S. Program (Progress Through Learning Understanding & Support)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01369030
Recruitment Status : Completed
First Posted : June 8, 2011
Results First Posted : June 3, 2014
Last Update Posted : June 3, 2014
InfoMedics, Inc.
Information provided by (Responsible Party):
Pamlab, Inc.

Brief Summary:
This study will be an observational study in which patients who have been prescribed Deplin® are invited to participate in surveys regarding their experiences with Deplin®. The purpose of this study is to increase the understanding of the role of L-methylfolate among patients who are candidates for Deplin®, provide patients with personalized education and support, and contribute to the overall understanding of the needs and concerns of patients being treated for depression.

Condition or disease Intervention/treatment
Major Depressive Disorder Other: Deplin®

Detailed Description:
Surveys used to conduct this study will be administered via telephone or online by InfoMedics, Inc., a company with a system for developing such patient-physician feedback programs. Participating physicians will ask their patients to participate in the program after Deplin® has been prescribed and provide them with a brochure containing an introduction to the program and instructions on how to enroll. Patients self-enroll, take a brief survey before starting their Deplin® prescription, and then a follow-up survey after 90 days of treatment with Deplin®. As patients complete surveys within the study, their physician will receive individualized feedback reports outlining their patient's treatment experience and progress. Patients will also receive a copy of their own reports, to help encourage them to continue taking Deplin® as directed. Patients will also receive educational materials about managing their depression.

Study Type : Observational
Actual Enrollment : 554 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: Deplin® P.L.U.S. Program (Progress Through Learning Understanding & Support)
Study Start Date : November 2010
Actual Primary Completion Date : April 2012
Actual Study Completion Date : April 2012

Resource links provided by the National Library of Medicine

Group/Cohort Intervention/treatment
Subjects with depression who have been prescribed Deplin® daily.
Other: Deplin®
Deplin® is an orally administered medical food available in a 7.5mg tablet or a 15mg caplet with each containing either 7.5mg or 15mg of L-methylfolate, respectively - which is the primary biologically active and immediately bioavailable form of folate. Dosage for this study will be 1 15mg caplet QD.

Primary Outcome Measures :
  1. Change in Depression Severity as Measured by the 9-item Patient Health Questionnaire (PHQ-9) [ Time Frame: Baseline to Endpoint (90 days) ]
    The PHQ-9 is a depression scale used to assess brief depression severity by rating symptoms and functional impairment experienced in the last two weeks. The questionnaire contains a total of 9 questions, and each question is scored on a range from 0-3. The minimum value "0" represents not at all, "1" several days, "2" indicates more than half the days, and the maximum value "3" stands for nearly every day. The total possible range is 0-27. The total number of each 0, 1, 2, 3 is added and multiplied by its value (0=0, 1=1, etc.) to produce a total score generated from the subtotal sum. The PHQ-9 total score is interpreted as follows: 0-4 represents minimal depression, 5-9 as mild depression, 10-14 as moderate depression, 15-19 moderately severe depression, and 20-27 severe depression.

Secondary Outcome Measures :
  1. Proportion of Patients Reporting Difficulty in Daily Functioning Due to Depressive Symptoms [ Time Frame: Baseline to Endpoint (90 days) ]
  2. Change in Overall Patient Satisfaction With Deplin® Using a 9-point Satisfaction Scale [ Time Frame: Baseline to Endpoint (90 days) ]
    Mean satisfaction with medication was rated on 1 to 9 point scale, 1 indicating "not at all satisfied" and 9 as "very satisfied."

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years to 70 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Sampling Method:   Probability Sample
Study Population
Patients with Depression Who Have Been Prescribed Deplin®

Inclusion Criteria:

  • New Deplin® Start
  • Only for patients with depression who have been prescribed brand name Deplin® to help metabolic management of depression.
  • Clinically depressed patients who have been prescribed Deplin® in combination with an antidepressant.
  • At the start of antidepressant therapy
  • As augmentation to antidepressant therapy

Exclusion Criteria:

  • Patients who do not meet DSM IV criteria for major depression
  • If participant indicates that he or she did not get a prescription for Deplin®, he/she will not be able to complete the survey(s).
  • For follow-up surveys, if the participant indicates that he/she has not been taking Deplin®, he/she will not be able to complete the survey(s).

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01369030

United States, North Carolina
Moses Cone Family Practice Center
Greensboro, North Carolina, United States, 27401
United States, Tennessee
Vanderbilt University School of Medicine
Nashville, Tennessee, United States, 37212
Sponsors and Collaborators
Pamlab, Inc.
InfoMedics, Inc.
Principal Investigator: Richard C Shelton, M.D. Vanderbilt University School of Medicine
Principal Investigator: Sloan Manning, M.D. Mood Disorders Clinic at Moses Cone Family Practice Center

Responsible Party: Pamlab, Inc. Identifier: NCT01369030     History of Changes
Other Study ID Numbers: D-009
First Posted: June 8, 2011    Key Record Dates
Results First Posted: June 3, 2014
Last Update Posted: June 3, 2014
Last Verified: May 2014

Keywords provided by Pamlab, Inc.:
combination therapy
folic acid
MTHFR genotype
C677T mutation
vitamin B6
vitamin B12

Additional relevant MeSH terms:
Depressive Disorder
Depressive Disorder, Major
Mood Disorders
Mental Disorders
Behavioral Symptoms